Latest Equity Capital News

Janus Electric Holdings reported a 46% increase in net loss to $4.93 million for the half-year ended December 2025, driven by rising costs despite a 33% revenue boost. The company faces funding uncertainties as it pursues key investments and operational scale-up.

Tribeca Global Natural Resources Limited reported a remarkable turnaround with a $69.5 million net profit for the half-year ended December 2025, alongside a fully franked dividend declaration. The company’s net tangible asset per share more than doubled, reflecting strong commodity market dynamics and strategic investment execution.

Euroz Hartleys Group Limited reported a robust half-year result for December 2025, with net profit more than doubling to $13.84 million, driven by strong growth in equity capital markets and advisory fees.

Amaero Ltd has announced plans to re-domicile from Australia to the United States, aiming to tap into larger capital markets and position itself for a potential US IPO by late 2026 or early 2027. The move retains its ASX listing while opening doors to broader investor pools and strategic growth opportunities.

Cash Converters International Limited has announced the recommencement of its Dividend Reinvestment Plan (DRP) effective 20 February 2026, restoring shareholders’ ability to reinvest dividends into additional shares with favourable terms.

Advanced Innergy Holdings Ltd (ASX:AIH) has reported a robust FY25 performance highlighted by a successful IPO and strong growth across its core segments, setting a confident tone for FY26.

Bell Financial Group delivered a robust 17.1% rise in net profit after tax to $36 million for 2025, driven by strong growth in its Platforms division and a rebound in market activity. The company declared a fully franked final dividend of 6.5 cents per share, signalling confidence as it prepares to launch a new wealth management platform in 2026.

Oneview Healthcare PLC reported a 21% increase in total revenue to €12 million for the year ended 31 December 2025, driven by growth in recurring revenue and customer expansion. Despite this, the company’s loss after tax widened to €12.6 million, reflecting ongoing investment and cost pressures.

PYC Therapeutics has initiated a substantial capital raising effort, aiming to secure up to A$653 million to propel its four RNA therapeutic candidates through critical clinical milestones. The retail entitlement offer opens today, following a successful institutional placement.

Cyclopharm Limited is accelerating its US market push for Technegas with a A$16 million capital raise following a record 2025 sales performance. The company aims to expand its US installations and advance new clinical applications beyond pulmonary embolism.

Nova Minerals plans to redomicile to the United States following the loss of its foreign private issuer status, while acquiring full ownership of its Estelle Gold and Critical Minerals Project and appointing a US-based CFO.

Resolution Minerals has taken a significant step towards expanding its footprint in the US capital markets by lodging a registration statement with the SEC and launching an ADR facility, while divesting a non-core Alaskan asset to focus on key US projects.